Overview
- In the phase 3 MajesTEC‑3 trial of 587 patients after 1–3 prior lines, Tec‑Dara cut the risk of progression or death by 83% versus daratumumab‑based triplets (HR 0.17) at a median 34.5 months of follow‑up.
- Thirty‑six‑month progression‑free survival was 83.4% with Tec‑Dara versus 29.7% with control, and overall survival was 83.3% versus 65.0% (HR 0.46).
- Deep responses were far more frequent with Tec‑Dara, including complete responses in about 82% versus about 32% and higher minimal residual disease negativity rates.
- Infections occurred more often with Tec‑Dara, including infection‑related deaths reported in the trial; investigators added immunoglobulin replacement and antimicrobial prophylaxis, after which infection rates declined over time.
- Both agents were given subcutaneously with step‑up dosing and convenient monthly administration after initial cycles, supporting potential community adoption compared with more resource‑intensive options such as CAR‑T.